Query: buprenorphineThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.

This page shows you your search results in order of date.

Pages: 1 2

71 records returned

FDA Approves 7-Day Buprenorphine Pain PatchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The FDA has approved a once-weekly buprenorphine transdermal system for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic. Medscape Medical News
Source: Medscape Today Headlines - July 8, 2010 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Purdue Pharma L.P. Receives FDA Approval For Butrans™ (buprenorphine) Transdermal System CIIIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Purdue Pharma L.P. announced that the U.S. Food and Drug Administration (FDA) approved Butrans™ (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days...
Source: Health News from Medical News Today - July 7, 2010 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

Purdue Pharma L.P. Receives FDA Approval for Butrans (buprenorphine) Transdermal System CIIIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
STAMFORD, Conn., July 1 /PRNewswire/ -- Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in...
Source: Drugs.com - New Drug Approvals - July 1, 2010 Category: Drugs & Pharmacology Source Type: news

Opioid-Dependent Patients Respond to TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Major Finding: Office-based buprenorphine/naloxone treatment was associated with a statistically significant decrease in participants reporting illegal activity, from 19% to 2%, and in interacting with the legal system, from 16% to 1%.
Source: Family Practice News - June 1, 2010 Category: Primary Care Authors: DIANA MAHONEY Tags: Mental Health Source Type: news

For Prescription Opioid Dependence, Relapses Associated With Shorter Treatment CourseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The largest treatment study ever conducted for prescription opioid dependence shows that tapering with buprenorphine during a 9-month period led to nearly universal relapse. Medscape Medical News
Source: Medscape Today Headlines - May 24, 2010 Category: Consumer Health News Tags: Psychiatry News Source Type: news

Buprenorphine Treatment Safer Than Methadone for Infants of Opiate-Addicted MothersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A large American study of the safety of buprenorphine in pregnancy finds that the drug results in lower neonatal abstinence scores than methadone, and shorter infant hospital stays. Medscape Medical News
Source: Medscape Today Headlines - May 21, 2010 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news

The NHS shouldn't be dishing out free drugs to addictsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Finger on the pulse: Heroin addicts must undergo intensive psychotherapy if they are ever to be cured.
Source: Telegraph Health - April 30, 2010 Category: Consumer Health News Tags: heroin morphine addicts buprenorphine buzz Source Type: news

Diverted Methadone and Buprenorphine Primarily Used to Prevent Withdrawal or to Stop Using HeroinEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Opioid agonist treatment (OAT) with methadone or buprenorphine is effective for reducing illicit drug use among opioid-dependent patients, but the diversion of these agents may be harmful.
Source: Alcohol, Tobacco and Other Drugs News - February 23, 2010 Category: Addiction Source Type: news

Alleviation of Opioid Withdrawal Symptoms Primary Driver of Illicit Buprenorphine UseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Illicit use of buprenorphine is primarily driven by a desire to alleviate symptoms of opioid withdrawal and not to get high. Medscape Medical News
Source: Medscape Today Headlines - December 10, 2009 Category: Consumer Health News Tags: Psychiatry Source Type: news

Titan Receives Notice Of Allowance For Probuphine(R) Patent Application In The Treatment Of Opiate AddictionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Titan Pharmaceuticals, Inc (Pink Sheets:TTNP) announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Titan's United States patent application directed to the use of Probuphine for the treatment of opiate addiction. The patent application is U.S. Application No. 10/453,377 filed June 2, 2003 titled "Implantable polymeric device for sustained release of buprenorphine"...
Source: Health News from Medical News Today - December 1, 2009 Category: Consumer Health News Tags: Alcohol / Addiction / Illegal Drugs Source Type: news

Researcher did not die of overdose, autopsy saysEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
University of Maryland pharmacologist Carrie John died from an allergic reaction and not because she injected a seemingly tainted batch of the narcotic buprenorphine, according to the state medical examiner. "There was nothing in her system to cause...
Source: OrlandoSentinel: Medical Research - November 13, 2009 Category: American Health Source Type: news

Expand Vets' Access to Methadone, Other Addiction Treatment, Report SaysEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The U.S. military's Tricare program is coming under fire for not providing reimbursement for methadone maintenance and buprenorphine treatment -- two leading pharmacological interventions for opioid addiction.
Source: Alcohol, Tobacco and Other Drugs News - November 11, 2009 Category: Addiction Source Type: news

DEA Letter Sparks Fears About Intimidation of Buprenorphine DocsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A recent letter from the Drug Enforcement Administration (DEA) to doctors certified to prescribe buprenorphine sparked concerns about intimidation and a perceived attempt to suppress the number of physicians prescribing the anti-opiate medication -- an impression that the Obama administration moved quickly to dispel.
Source: Alcohol, Tobacco and Other Drugs News - October 1, 2009 Category: Addiction Source Type: news

Half of U.S. Prisons Fail to Adequately Treat Opiate AddictionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Opiate-replacement therapy (ORT) such as methadone and buprenorphine are available in only about half of all federal and state prison systems, and just 23 states provide referrals to addiction treatment upon release from prison, according to new research.
Source: Alcohol, Tobacco and Other Drugs News - September 11, 2009 Category: Addiction Source Type: news

Buprenorphine-naloxone A Helpful Addition To Opioid Substitution Treatment, AustraliaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
People who inject drugs may be less likely to inject buprenorphine-naloxone than other opioid substitutes, according to the results of a recent study published in the Medical Journal of Australia. Buprenorphine is used to treat heroin dependence.
Source: Health News from Medical News Today - August 5, 2009 Category: Consumer Health News Tags: Alcohol / Addiction / Illegal Drugs Source Type: news

Transdermal Opioid Switch Improves Cancer AnalgesiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In patients with poorly controlled chronic cancer pain, switching from transdermal buprenorphine to transdermal fentanyl and vice versa allows dose reduction and prompts a significant improvement in analgesic effect, Italian researchers report in a May 7th publication in the Journal of Experimental & Clinical Cancer Research. Reuters Health Information
Source: Medscape Medical News Headlines - June 8, 2009 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Extended Outpatient Detoxification with Buprenorphine Demonstrates Better Outcomes than Short-Term DetoxificationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Researchers compared outcomes for short- and long-term detoxification with buprenorphine to determine how best to maximize completion rates, reduce drug use after completion, and facilitate transition to longer term treatment.
Source: Alcohol, Tobacco and Other Drugs News - June 5, 2009 Category: Addiction Source Type: news

Concern in Wisconsin over Suboxone-Related DeathsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The recent Suboxone-related deaths of two Milwaukee-area residents has drawn negative attention to federal rules that allow patients to use the buprenorphine-based drug at home.
Source: Alcohol, Tobacco and Other Drugs News - April 7, 2009 Category: Addiction Source Type: news

BEMA Buprenorphine To Proceed To Phase 2 Following Favorable Initial Study ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced preliminary results from a Phase 1 study assessing two new formulations of the opioid analgesic buprenorphine utilizing the company's proprietary BEMA™ drug delivery technology.
Source: Health News from Medical News Today - March 20, 2009 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

BEMA Buprenorphine to Proceed to Phase 2 Following Favorable Initial Study ResultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
BioDelivery Sciences' Second Product Using the BEMA Drug Delivery Technology to Enter Phase 2 in June RALEIGH, N.C.--(BUSINESS WIRE)--Mar 18, 2009 - BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced preliminary results from a Phase 1...
Source: Drugs.com - Clinical Trials - March 18, 2009 Category: Pharmaceuticals Source Type: news

Buprenorphine for Opioid Dependence: Why Is It Underprescribed?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, investigators asked physicians involved in 1 of 2 buprenorphine initiatives to complete surveys assessing factors likely to affect their willingness to prescribe buprenorphine.
Source: Alcohol, Tobacco and Other Drugs News - February 12, 2009 Category: Addiction Source Type: news

Longer Treatment with Buprenorphine-Naloxone Improves Outcomes in Opioid-dependent Young AdultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The use of long-term opioid agonist and partial agonist medication is often reserved for older opioid-dependent individuals, while a brief detoxification with medication or medication-free treatment is offered to younger individuals. In a randomized trial, researchers evaluated the efficacy of buprenorphine-naloxone tapers of 2 versus 12 weeks in younger subjects.
Source: Alcohol, Tobacco and Other Drugs News - January 14, 2009 Category: Addiction Source Type: news

Encore Therapeutics Inc. Demonstrates Proof Of Concept For A Long-Acting Buprenorphine Depot For Pain And Drug Abuse Therapy (ETI-311)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Encore Therapeutics Inc. (ETI) today reported that ETI-311, the company's novel long-acting depot for buprenorphine, produced clinically relevant plasma levels of the drug over 3-7 days when administered by intradermal injection in dog studies.
Source: Health News from Medical News Today - December 10, 2008 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news

Encore Therapeutics Inc. Demonstrates Proof of Concept for a Long-acting Buprenorphine Depot for Pain and Drug Abuse Therapy (ETI-311)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CARLSBAD, Calif.--(BUSINESS WIRE)--Dec 8, 2008 - Encore Therapeutics Inc. (ETI) today reported that ETI-311, the company's novel long-acting depot for buprenorphine, produced clinically relevant plasma levels of the drug over 3-7 days when...
Source: Drugs.com - Clinical Trials - December 8, 2008 Category: Pharmaceuticals Source Type: news

Buprenorphine with Drug Counseling Is Superior to Oral Naltrexone with Counseling or Counseling Alone for Heroin DependenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
null
Source: Alcohol, Tobacco and Other Drugs News - November 21, 2008 Category: Addiction Source Type: news

Extended Agonist Therapy Substantially Improves Outcomes in Opioid-Addicted YouthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Extended therapy with buprenorphine-naloxone improves outcomes in opioid-addicted youth and may offer clinicians a new, significantly more effective treatment option for this patient population. Medscape Medical News
Source: Medscape Today Headlines - November 10, 2008 Category: Consumer Health News Tags: Psychiatry Source Type: news

Extended Agonist Therapy Substantially Improves Outcomes in Opioid-Addicted YouthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Extended therapy with buprenorphine-naloxone substantially improves outcomes in opioid-addicted youth and may offer clinicians a new, significantly more effective treatment option for this growing patient population. Medscape Medical News
Source: Medscape Medical News Headlines - November 7, 2008 Category: Consumer Health News Tags: Psychiatry Source Type: news

Somewhat Better Outcomes With Longer-Term Treatment For Opioid-Addicted YouthEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New research published in the November 5 issue of JAMA reveals that long-term therapy rather than short-term therapy for opioid-addicted adolescents yields better results. Those who received continuing treatment with the combination medication buprenorphine-naloxone were less likely to test positive for opioids and reported lower rates of opioid use compared to adolescents who participated in a short-term detoxification program with the same medication.
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today - November 5, 2008 Category: Addiction Tags: Alcohol / Addiction / Illegal Drugs Source Type: news

Extended Suboxone Treatment Substantially Improves Outcomes For Opioid-Addicted Young Adults - Preferable To Detox And Standard Counseling AloneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In the first clinical trial of a medication that was used for an extended time to treat opioid addiction in young adults, participants who received counseling and Suboxone (buprenorphine-naloxone) for 12 weeks had substantially better outcomes than those who received the standard treatment of short-term detoxification and counseling.
Source: Health News from Medical News Today - November 4, 2008 Category: Consumer Health News Tags: Alcohol / Addiction / Illegal Drugs Source Type: news

Extended Suboxone Treatment Substantially Improves Outcomes for Opioid-Addicted Young AdultsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In the first clinical trial of a medication that was used for an extended time to treat opioid addiction in young adults, participants who received counseling and Suboxone (buprenorphine-naloxone) for 12 weeks had substantially better outcomes than those who received the standard treatment of short-term detoxification and counseling. The study, published November 5 in the "Journal of the American Medical Association," was conducted through the National Drug Abuse Treatment Clinical Trials Network supported by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH).
Source: National Institutes of Health (NIH) News Releases - November 4, 2008 Category: American Health Source Type: news

Opioid Agonist Treatment for Teen Addicts Better than Detox and CounselingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
PHILADELPHIA (MedPage Today) -- Young opioid addicts stayed clean longer when they received extended treatment with buprenorphine and naloxone (Suboxone) compared with short-term detoxification followed by counseling, researchers here said.
Source: MedPage Today Psychiatry - November 4, 2008 Category: Psychiatry Source Type: news

NAABT Matches 14,000 Addicted Patients with PhysiciansEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The National Alliance of Advocates for Buprenorphine Treatment's free and anonymous online matching system has connected 14,000 addicted patients with physicians certified to prescribe Suboxone for opioid addiction.
Source: Alcohol, Tobacco and Other Drugs News - October 22, 2008 Category: Addiction Source Type: news

Transdermal Buprenorphine Effective for Severe Cancer PainEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Transdermal buprenorphine appears to be effective and safe in a study of patients with severe cancer-related pain, European investigators report in the Journal of Pain and Symptom Management. Reuters Health Information
Source: Medscape Medical News Headlines - October 1, 2008 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Titan Pharmaceuticals Announces Positive Results From Phase III Clinical Trial Of Probuphine For The Treatment Of Opioid AddictionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Titan Pharmaceuticals, Inc. (AMEX:TTP) announced positive, statistically significant results from its randomized, double-blind, placebo controlled, multi-center Phase III clinical trial of Probuphine®. Probuphine is Titan's novel, subcutaneous implant formulation designed using its ProNeura technology to deliver six months of buprenorphine. Buprenorphine is currently marketed as a sublingual formulation for the treatment of opioid addiction.
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today - July 30, 2008 Category: Addiction Tags: Alcohol / Addiction / Illegal Drugs Source Type: news

Recovering Heroin Addicts Fare Better on Opiate Maintenance TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Detoxified heroin addicts receiving buprenorphine maintenance therapy had superior heroin abstinence to those on naltrexone, in a recent trial in Malaysia. Medscape Medical News
Source: Medscape Medical News Headlines - July 2, 2008 Category: Consumer Health News Tags: Psychiatry Source Type: news

Buprenorphine Beats Naltrexone in Heroin Treatment, Study SaysEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Opiate addicts given the anti-addiction medication buprenorphine -- an alternative to methadone maintenance -- were twice as likely to remain abstinent and half as likely to relapse as patients taking naltrexone, an opioid receptor antagonist, researchers say.
Source: Alcohol, Tobacco and Other Drugs News - July 2, 2008 Category: Addiction Source Type: news

Opioid Maintenance Therapy Saves LivesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study examines predictors of long-term mortality in heroin-dependent patients who had participated in a randomized trial comparing methadone and buprenorphine.
Source: Alcohol, Tobacco and Other Drugs News - June 4, 2008 Category: Addiction Source Type: news

Review: buprenorphine-nalaxone for opioid dependenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
National electronic Library for Medicines (NeLM)
Source: CEBMH News | News Front Page - May 20, 2008 Category: Health Management Tags: Category Source Type: news

Critics Say Health Plans Put Lives at Risk by Requiring Prior Approval for BuprenorphineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A major healthcare provider recently announced that it would begin requiring preauthorization for prescriptions of the buprenorphine-based addiction medications Suboxone and Subutex, a move that has raised concern among physicians and patient-advocacy groups about erecting new barriers to treatment.
Source: Alcohol, Tobacco and Other Drugs News - May 16, 2008 Category: Addiction Source Type: news

Feds Detail Plan to Prevent Abuse of BuprenorphineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Federal drug officials recently detailed a plan to control diversion and abuse of an anti-addiction medication that was specifically designed to resist such problems.
Source: Alcohol, Tobacco and Other Drugs News - February 25, 2008 Category: Addiction Source Type: news

SAMHSA Delayed Reporting of Bupe ProblemsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Substance Abuse and Mental Health Services Administration (SAMHSA) knew as early as December 2005 that some patients were crushing and injecting buprenorphine -- a drug designed to prevent just such abuse -- but didn't release the findings until January 2008.
Source: Alcohol, Tobacco and Other Drugs News - February 19, 2008 Category: Addiction Source Type: news

Experts See Growing Illegal Market for BuprenorphineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Buprenorphine (Suboxone) was developed as an alternative to methadone that would be equally effective in treating opiate addiction but less likely to be abused. But Baltimore officials say that a black market for the drug has developed, leading to "bupe" abuse and some deaths.
Source: Alcohol, Tobacco and Other Drugs News - December 17, 2007 Category: Addiction Source Type: news

PCT produces good practice checklist for prescribers of methadone and buprenorphineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
National electronic Library for Medicines (NeLM)
Source: CEBMH News | News Front Page - August 1, 2007 Category: Health Management Tags: Category Source Type: news

High Costs Due To Increased Fracture Risks With OpioidsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Opioids are widely used for many chronic pain conditions, but have been shown to increase fracture risks. However, fracture risks are lowest with buprenorphine compared to other opioids, such as tramadol, morphine, fentanyl and oxycodone.A recent study evaluated the costs related to opioid-induced fractures in Germany, considering treatment costs of hip, spine and forearm fractures and number of patients at risk in Germany. [click link for full article]
Source: Pain / Anesthetics News From Medical News Today - August 1, 2007 Category: Anesthesiology Source Type: news

Bupe Tangled in Red TapeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Maryland has probably done more than any state to promote use of the anti-opiate drug buprenorphine, but many doctors in the state remain unwilling to prescribe the drug.
Source: Alcohol, Tobacco and Other Drugs News - July 23, 2007 Category: Addiction Source Type: news

Buprenorphine Test in Maryland Yields Some SuccessEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sixty-five percent of opiate addicts taking part in a buprenorphine trial in Maryland stayed in treatment for at least six months, officials said.
Source: Alcohol, Tobacco and Other Drugs News - July 20, 2007 Category: Addiction Source Type: news

NIDA to Study Treatment for Painkiller AddictionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The National Institute on Drug Abuse is investigating whether Suboxone -- a mix of buprenorphine and naloxone -- is effective in treating patients addicted to prescription opiate-based painkillers.
Source: Alcohol, Tobacco and Other Drugs News - July 16, 2007 Category: Addiction Source Type: news

Bureaucracy Versus BuprenorphineEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bureaucratic hurdles and low Medicaid reimbursement rates are discouraging doctors from prescribing buprenorphine to treat opiate addictions, according to a survey from the Center for a Healthy Maryland.
Source: Alcohol, Tobacco and Other Drugs News - June 21, 2007 Category: Addiction Source Type: news

Waismann Method Survey Reveals Dependency Risk for People Using SuboxoneEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Waismann Method announced findings from an online survey of Suboxone users, indicating that 66 percent of individuals currently taking Suboxone, also known as Subutex or Buprenorphine, believe they cannot stop taking the drug without assistance, indicating a physical dependency. Suboxone is often prescribed to treat dependency to opiates including OxyContin, Vicodin, Lortab or Fentanyl. Because Suboxone is 50 percent opiate in composition, it helps alleviate painful withdrawal symptoms caused by the original opiate, but still remains a replacement therapy that substitutes one opiate-based drug with another. (PRWeb Jun ...
Source: PRWeb: Medical Pharmaceuticals - June 6, 2007 Category: Pharmaceuticals Source Type: news

Newsdesk: Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care SetEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Author: NewsEditor Subject: Treating Opioid Addiction With Buprenorphine-Naloxone in Community-Based Primary Care Set Posted: Thu 17 May 2007 1:05 am (GMT 1) Should greater numbers of patients have access to buprenorphine treatment in nonspecialized settings? <br><i>Annals of family medicine</i> ...view forum post_________________News Editor, CounsellingResource.com Also see our Daily Mental Health News Page
Source: CounsellingResource.com News and Features - May 17, 2007 Category: Psychiatry & Psychology Authors: NewsEditor Tags: News in Psychology, Therapy and Mental Health Source Type: news

Pages: 1 2